Voriconazole, a second-generation triazole, has recently been appro ved by t he Food and Drug Administration (FDA) to treat invasive aspergillosis and refrac tory infections with Scedosporium apiospermum or Fusarium spp. The reported side -effects of voriconazole include visual changes, headaches, elevated hepatic e nzymes, Steven-Johnson syndrome, toxic epidermal necrolysis, chelitis, photose nsitivity, discoid lupus erythematosus and anaphylactoid infusion reactions. Pse udoporphyria was first described in association with nalidixic acid. It has the same clinical and histologic features as porphyria cutanea tarda (PCT) but is di stinguished by normal porphyrin levels in the serum, urine and stool. We present the case of a patient who developed pseudoporphyria after receiving treatment w ith voriconazole. Voriconazole, a second-generation triazole, has recently been ved by the he Food and Drug Administration (FDA) to treat invasive aspergillosis and refrac tory infections with Scedosporium apiospermum or Fusarium spp. The reported side-effects of voriconazole include visual changes, headaches , elevated hepatic e nzymes, Steven-Johnson syndrome, toxic epidermal necrolysis, chelitis, photosensitivity, discoid lupus erythematosus and anaphylactoid infusion reactions. Pse udoporphyria was first described in association with nalidixic acid. It has the same clinical and histologic features as porphyria cutanea tarda (PCT) but is di stingished by normal porphyrin levels in the serum, urine and stool. We present the case of a patient who developed pseudoporphyria after receiving treatment w ith voriconazole.